Arben Ventures

Arben Ventures is an early-stage deep-tech health venture capital firm founded by researchers from Stanford's Department of Genetics and directors of the Stanford Healthcare Innovation Lab. The firm focuses on investing in startups that are shaping the future of healthcare and personalized medicine, with a particular emphasis on precision medicine, multi-omics, early cancer detection, women's health, mental health, and longevity. Arben Ventures aims to accelerate technologies that can improve the health and happiness of millions of people.

The firm's investment strategy involves writing initial checks ranging from $25,000 to $50,000 for pre-seed and seed-stage health startups, typically at valuations under $12 million. They also provide follow-on investments of up to $500,000 to support portfolio companies as they launch, scale, and grow. Arben Ventures is managed by PhD professionals who conduct due diligence and offer ongoing support to portfolio teams, leveraging their unique access to the research ecosystem ranked #1 in the world for genomics and leading in precision medicine, longevity, multi-omics, and wearables.

Arben Ventures was founded in 2023 by Ariel Ganz and Ben Rolnik, who recognized a gap in healthcare innovation where transformative ideas often fail to make it out of the lab due to a lack of funding. Their mission is to support pre-seed and seed founders at the intersection of medicine and technology, providing the necessary resources to turn promising ideas into successful companies. The firm's portfolio companies have the potential to improve care by collecting and using health data in smarter ways, building novel medical devices, and democratizing access to high-quality treatment.